Jim Scopa

James Paul Scopa is currently Director at Astute Medical, Inc., Independent Director at Aligos Therapeutics, Inc. since 2021, Director at DICE Molecules SV, Inc. since 2020, Director at Neuron23, Inc., and Venture Partner at Oneventures Management.
Former roles include Managing Director at Cash Reserve Fund, Inc., Director at TriVascular, Inc., Independent Director at Conatus Pharmaceuticals, Inc. from 2011 to 2018, Director at Peplin, Inc. from 2006 to 2009, Director at Kalidex Pharmaceuticals, Inc., Managing Director at MPM BioImpact LLC from 2005 to 2017, Director at Nevro Corp., Independent Director at Trivascular Technologies, Inc. from 2008 to 2016, Director at Trivascular2, Inc., Director at Solasia Pharma KK, Director at iPierian, Inc., Director at True North Therapeutics, Inc., Director at Semma Therapeutics, Inc., Independent Director at DICE Therapeutics, Inc. from 2020 to 2023, Director at Blade Therapeutics, Inc. from 2015 to 2023, Independent Director at Adverum Biotechnologies, Inc. from 2019 to 2025, Principal at Thomas Weisel Partners LLC from 2002 to 2004, Principal at Alex.
Brown & Sons, Inc., and Principal at Deutsche Bank Corp.
from 1999 to 2001.
Education includes an MBA from Harvard Business School conferred in 1986, graduate degree from Harvard Law School conferred in 1986, and undergraduate degree from Harvard College conferred in 1980.